Abstract
3-Quinuclidinyl benzilate (BZ) ranks among incapacitating military warfare agents. It acts as a competitive inhibitor on muscarinic receptors leading to non-lethal mental impairment.
The present study aimed to investigate toxicokinetics of BZ in rats. Moreover, BZ can be exploited to produce a pharmacological model of Alzheimer's disease; thus, this paper focuses mainly on the BZ distribution to the brain.
Wistar rats were administered i.p. with BZ (2 and 10 mg/kg). The BZ concentration was determined using LC-MS/MS in plasma, urine, bile, brain, kidney and liver.
The sample preparation was based on a solid phase extraction (liquids) or protein precipitation (organ homogenates). The plasma concentration peaked at 3 min (204.5 +/- 55.4 and 2185.5 +/- 465.4 ng/ml).
The maximal concentration in the brain was reached several minutes later. Plasma elimination half-life was 67.9 +/- 3.4 in the 2 mg/kg group and 96.6 +/- 27.9 in the 10 mg/kg group.
BZ concentrations remained steady in the brain, with slow elimination (t(1/2) 506.9 +/- 359.5 min). Agent BZ is excreted mainly via the urine.
Steady BZ concentration in the brain could explain the previously published duration of the significant impairment in passive avoidance tasks in rats after an injection of BZ.